<DOC>
	<DOCNO>NCT02425735</DOCNO>
	<brief_summary>In study , effect γδT cell human hepatocellular liver cancer combination tumor reduce surgery , example cryosurgery go investigate .</brief_summary>
	<brief_title>Safety Efficiency γδ T Cell Against Hepatocellular Liver Cancer</brief_title>
	<detailed_description>Liver tumor remove use tumor reduce surgery cryosurgery . PBMC patient separate peripheral blood . After make potential cancer killer γδ T Cell DC-CIK , infuse patient immunotherapy treatment .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Age:1875 2 . Karnofsky performance status &gt; 50 3 . Diagnosis hepatocellular carcinoma cancer base histology current accept radiological measure . 4 . Classification tumor , node , metastasisclassification ( TNM ) stage : Ⅱ , Ⅲ , Ⅳ 5 . Will receive cryosurgery , gd Tcells/ DCCIK . 6 . Life expectancy : Greater 3 month 7 . Ability understand study protocol willingness sign write informed consent document 1 . Patients kinds cancer 2 . History coagulation disorder anemia 3 . Patients heart disease diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Immunotherapy , γδ T Cell , heptocellular liver cancer</keyword>
</DOC>